CCDC85B Inhibitors
CCDC85B inhibitors are a diverse class of compounds that interfere with various signaling pathways potentially linked to the regulatory mechanisms of CCDC85B. For example, compounds like Rapamycin and LY294002 target the mTOR and PI3K/AKT pathways, respectively, which are crucial for processes such as autophagy and protein synthesis that could be central to CCDC85B's function. By inhibiting these pathways, these compounds indirectly restrain the functional environment necessary for CCDC85B activity. Disruption of mTORC1 signaling by Rapamycin is particularly significant as it is a central node in cellular growth regulation, and any functional association of CCDC85B with this pathway suggests that its inhibition could have broad implications for CCDC85B's role in the cell.
LY294002, U0126, SB203580, Wortmannin, and others, suggests that CCDC85B may be implicated in a network of signaling pathways, each contributing to different cellular functions such as cell cycle progression, stress response, apoptosis, and more. The inhibition of these pathways by the respective compounds can lead to a decrease in CCDC85B activity either by direct inhibition of the protein's function or by altering the cellular state in a way that makes the environment less conducive for CCDC85B to act effectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTORC1, which is a key regulator of autophagy and protein synthesis. If CCDC85B function is tied to autophagy regulation or protein synthesis through mTORC1 signaling, the inhibition of mTORC1 by Rapamycin would directly lead to decreased functional activity of CCDC85B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, reducing AKT phosphorylation and subsequent mTORC1 signaling. Inhibition of mTORC1 by LY294002 would reduce CCDC85B activity if CCDC85B is regulated by mTORC1-mediated signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of ERK1/2. If CCDC85B activity is influenced by ERK1/2-mediated signaling, such as in cell cycle regulation, the inhibition of ERK1/2 by U0126 would lead to decreased activity of CCDC85B. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which is involved in stress responses and apoptosis. If CCDC85B is implicated in cellular responses to stress and inflammation that are mediated by p38 MAPK, the inhibition of p38 MAPK by SB203580 would lead to decreased CCDC85B activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that prevents the formation of PIP3 and thus inhibits AKT activation. If CCDC85B is active downstream of the AKT pathway in cell survival and growth, the inhibition of AKT by Wortmannin would lead to decreased functional activity of CCDC85B. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which leads to a reduction in ERK1/2 activation. If CCDC85B's activity is regulated via the ERK1/2 signaling pathway, inhibition by PD98059 would reduce CCDC85B activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. If CCDC85B is involved in JNK signaling, particularly in response to cellular stress, the inhibition of JNK by SP600125 would lead to decreased CCDC85B activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that could lead to the accumulation of misfolded proteins. If CCDC85B is regulated by proteasomal degradation, inhibition of the proteasome by Bortezomib would increase CCDC85B levels initially, but the subsequent stress and potential activation of cell cycle arrest mechanisms might lead to decreased activity of CCDC85B as part of a broader cellular response to proteasome inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. If CCDC85B is regulated by a tyrosine kinase signaling pathway, inhibition of these kinases by Dasatinib would lead to decreased CCDC85B activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases including RAF, which is part of the MAPK signaling pathway. If CCDC85B is regulated by the RAF/MEK/ERK signaling cascade, inhibition by Sorafenib would lead to decreased CCDC85B activity. | ||||||